Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D G Bichet

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|April 7, 1988
Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidusD G Bichet, M Razi, M Lonergan, et al.
The Journal of Biological Chemistry|July 5, 1996
A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activationT E Hebert, S Moffett, J P Morello, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|May 1, 1994
Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutantW Rosenthal, A Seibold, A Antaramian, et al.
Kidney International|June 1, 1986
Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failureD G Bichet, C Kortas, B Mettauer, et al.
Nature|September 17, 1992
Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidusW Rosenthal, A Seibold, A Antaramian, et al.
Molecular Genetics and Metabolism|February 19, 2014
Outcomes of patients treated through the Canadian Fabry disease initiativeS M Sirrs, D G Bichet, R Casey, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteersE Bellissant, T Denolle, P Sinnassamy, et al.
Kidney International|November 1, 1989
Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanismD G Bichet, M Razi, M F Arthus, et al.
Kidney International|August 1, 1985
Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patientsM D Shapiro, K M Nicholls, B M Groves, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 14, 1999
Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phasesJ M Le Mellédo, S Merani, D Koszycki, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|April 7, 1988
Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidusD G Bichet, M Razi, M Lonergan, et al.
The Journal of Biological Chemistry|July 5, 1996
A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activationT E Hebert, S Moffett, J P Morello, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|May 1, 1994
Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutantW Rosenthal, A Seibold, A Antaramian, et al.
Kidney International|June 1, 1986
Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failureD G Bichet, C Kortas, B Mettauer, et al.
Nature|September 17, 1992
Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidusW Rosenthal, A Seibold, A Antaramian, et al.
Molecular Genetics and Metabolism|February 19, 2014
Outcomes of patients treated through the Canadian Fabry disease initiativeS M Sirrs, D G Bichet, R Casey, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1996
Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteersE Bellissant, T Denolle, P Sinnassamy, et al.
Kidney International|November 1, 1989
Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanismD G Bichet, M Razi, M F Arthus, et al.
Kidney International|August 1, 1985
Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patientsM D Shapiro, K M Nicholls, B M Groves, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 14, 1999
Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phasesJ M Le Mellédo, S Merani, D Koszycki, et al.
Pageof 8